CNVN 202

Drug Profile

CNVN 202

Alternative Names: Chol-fus1; Cholesterol-Fus1 liposome complex; DOTAP; DOTAP:Chol-fus1; DOTAP:chol-TUSC2; FUS1 cancer gene therapy; FUS1-DOTAP:cholesterol; INGN-401; Nanoparticle formulation FUS-1; Oncoprex; Oncoprex nanovesicles; TUSC2; TUSC2/FUS1

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Introgen Therapeutics
  • Developer Genprex
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action FUS1 tumour suppressor gene transcription stimulants; FUS1 tumour suppressor protein stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 06 Jan 2017 Interim efficacy data from a phase II trial in Non-small cell lung cancer released by Genprex (9209884; 9238240)
  • 24 Aug 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Second-line therapy or greater) in USA before August 2016 (IV) (NCT01455389)
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top